Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | $10,267 | — | $14,000 | — |
| Operating expenses: | ||||
| Research and development | 30,994 | 34,664 | 57,807 | 59,719 |
| General and administrative | 10,963 | 10,454 | 22,096 | 20,296 |
| Total operating expenses | 41,957 | 45,118 | 79,903 | 80,015 |
| Loss from operations | (31,690) | (45,118) | (65,903) | (80,015) |
| Other income: | ||||
| Interest income | 9,718 | 11,260 | 19,570 | 22,649 |
Item 1. Financial Statements.
FAQ
- What is Janux Therapeutics's R&D?
- Janux Therapeutics (JANX) reported R&D of $30.99M in Q2 2026.
- How has Janux Therapeutics's R&D changed year-over-year?
- Janux Therapeutics's R&D decreased by 10.6% year-over-year, from $34.66M to $30.99M.
- What is the long-term trend for Janux Therapeutics's R&D?
- Over 4 years (2021 to 2025), Janux Therapeutics's R&D has grown at a 48.0% compound annual growth rate (CAGR), from $26.24M to $125.9M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Janux Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude